<DOC>
	<DOC>NCT01988662</DOC>
	<brief_summary>This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept. Free plasma VEGF-A level was measured in this study .</brief_summary>
	<brief_title>UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Inclusion Criteria Newly diagnosed Agerelated Macular Degeneration (AMD) No previous treatment received for diagnosed AMD Visual Acuity 6/7.5 to 6/96 Key standard exclusion criteria for antiVEGF treatment Visual Acuity &lt;6/96 nAMD in both eyes, or any condition in other eye which may have required anti VEGF treatment during study period other disease in candidate eye which could have compromised visual acuity or required medical/surgical intervention during study period participation to other clinical study with 'not approved' treatment within a year prior to UNRAVEL study participation.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nAMD, VEGF, VEGF agent, BCVA, CRT, Ranibizumab, Lucentis, Aflibercept, Eylea</keyword>
</DOC>